Literature DB >> 3263049

Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease.

T Ghayur1, T A Seemayer, A Xenocostas, W S Lapp.   

Abstract

This study presents the sequential morphologic regeneration of graft-vs.-host (GVH)-induced dysplastic thymuses in long-term survivors of GVH reactions. GVH reactions were induced in adult C57BL/6xAF1 (B6AF1) hybrids by injecting 20 x 10(6) A strain parental lymphoid cells (PLC). Starting on day 30 after GVH induction, five to ten animals were randomly selected from a pool of GVH-reactive mice and killed at various times. Each animal was tested for thymic histology and T cell functions. Thymuses taken on day 30 after GVH induction displayed severe dysplasia as characterized by lymphocytic depletion, complete effacement of cortico-medullary demarcation, and reduction and total loss of medullary epithelial cells or both. Starting by days 60-70 after GVH induction, at least four stages of thymic regeneration were identified. Day 60-70 thymuses displayed cortical regeneration and the reappearance of cortico-medullary demarcation. The medulla of these thymuses, although containing dark individual epithelial cells and numerous lymphocytes, was devoid of pale epithelial cells (stage 1). The medulla of thymuses on day 100 after GVH induction displayed a few sparcely distributed pale epithelial cells and numerous lymphocytes as well as dark epithelial cells (stage 2). The medulla of thymuses examined 130 days after GVH induction displayed numerous pale individual epithelial cells and a few pale epithelial cell clusters. Such thymuses also showed a reduction in the number of medullary lymphocytes (stage 3). Finally, the medulla of thymuses 150-160 days after GVH induction displayed numerous pale epithelial cell clusters and Hassall's bodies. These thymuses were indistinguishable from normal adult thymuses (stage 4). All of the animals tested up to day 130 after GVH induction showed no significant T cell function. Animals displaying stage 4 of thymic regeneration showed significant proliferative responses to T cell mitogen, concanavalin A (conA), and six of ten animals also displayed a few plaque forming cells (PFC) to sheep red blood cells (SRBC) in their spleens. Furthermore, all animals (10 of 10) killed on day 180 after GVH induction displayed significant T cell functions.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3263049      PMCID: PMC1880640     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors.

Authors:  D R Noel; R P Witherspoon; R Storb; K Atkinson; K Doney; E M Mickelson; H D Ochs; R P Warren; P L Weiden; E D Thomas
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

2.  Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers.

Authors:  H Rappaport; A Khalil; O Halle-Pannenko; L Pritchard; D Dantchev; G Mathé
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

Review 3.  Intrathymic and extrathymic T cell maturation.

Authors:  O Stutman
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

4.  Thymic epithelial injury in graft-versus-host reactions following adrenalectomy.

Authors:  T A Seemayer; W S Lapp; R P Bolande
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

Review 5.  Thymus and lymphohemopoietic cells: their role in T cell maturation in selection of T cells' H-2-restriction-specificity and in H-2 linked Ir gene control.

Authors:  R M Zinkernagel
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

Review 6.  The Graft-versus-Host Reaction: a pathogenetic mechanism of experimental and human disease.

Authors:  T A Seemayer
Journal:  Perspect Pediatr Pathol       Date:  1979

7.  Thymic involution in murine graft-versus-host reaction. Epithelial injury mimicking human thymic dysplasia.

Authors:  T A Seemayer; W S Lapp; R P Bolande
Journal:  Am J Pathol       Date:  1977-07       Impact factor: 4.307

8.  The thymus in patients with allogeneic bone marrow transplants.

Authors:  W E Beschorner; G M Hutchins; G J Elfenbein; G W Santos
Journal:  Am J Pathol       Date:  1978-07       Impact factor: 4.307

9.  Tracing of cells of the avian thymus through embryonic life in interspecific chimeras.

Authors:  N M Le Douarin; F V Jotereau
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

10.  Experimental studies on the development of the thymus.

Authors:  M A Moore; J J Owen
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

View more
  13 in total

1.  Pulmonary endothelial chimerism after hematopoietic stem cell transplantation.

Authors:  Kyoko Hijiya; Toyofumi Fengshi Chen-Yoshikawa; Aya Miyagawa-Hayashino; Tadakazu Kondo; Akihiro Aoyama; Hironori Haga; Akifumi Takaori-Kondo; Hiroshi Date
Journal:  Surg Today       Date:  2017-07-08       Impact factor: 2.549

2.  Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants.

Authors:  Samantha Herretes; Duncan B Ross; Stephanie Duffort; Henry Barreras; Tan Yaohong; Ali M Saeed; Juan C Murillo; Krishna V Komanduri; Robert B Levy; Victor L Perez
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

3.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

Review 4.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

Review 5.  T cell immune reconstitution following lymphodepletion.

Authors:  Kirsten M Williams; Frances T Hakim; Ronald E Gress
Journal:  Semin Immunol       Date:  2007-11-19       Impact factor: 11.130

Review 6.  Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Ronald E Gress
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

7.  Increased expression of proopiomelanocortin (POMC) mRNA in adrenal glands of mice undergoing graft-versus-host disease (GVHD): association with persistent elevated plasma corticosterone levels.

Authors:  K E You-Ten; A Itié; T A Seemayer; R G Palfree; W S Lapp
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 8.  The immunopathology of thymic GVHD.

Authors:  Werner Krenger; Georg A Holländer
Journal:  Semin Immunopathol       Date:  2008-10-31       Impact factor: 9.623

Review 9.  Biology of chronic graft-versus-host disease: implications for a future therapeutic approach.

Authors:  Paul J Martin
Journal:  Keio J Med       Date:  2008-12

Review 10.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.